PhillipCapital

Broker's Calls

Analysts positive on Hyphens Pharma’s expansion into new markets

PhillipCapital and SAC Capital have kept “buy” on Hyphens at unchanged target prices of 35 cents and 38 cents respectively.
PhillipCapital lowers TP on 17Live to $1.80, anticipates revenue and margins recovery in 2HFY2024 - THE EDGE SINGAPORE

Broker's Calls

PhillipCapital lowers TP on 17Live to $1.80, anticipates revenue and margins recovery in 2HFY2024

17Live is not immune to the pronounced industry-wide trend of post-pandemic decline in MAUs, the analysts highlight.

Broker's Calls

Analysts mostly keep estimates on UOB after 2QFY2024 core net profit stood within expectations

Analysts have all kept their "buy", "hold" and "sell" calls after UOB's 2QFY2024 results.

Broker's Calls

Analysts mostly raise SGX’s target price estimates after FY2024 results

The analysts' target prices range from $10.20 to $10.80.
PhillipCapital upgrades Sembcorp to ‘buy’ from ‘accumulate’ at raised target price, Maybank keeps ‘buy’ - THE EDGE SINGAPORE

Broker's Calls

PhillipCapital upgrades Sembcorp to ‘buy’ from ‘accumulate’ at raised target price, Maybank keeps ‘buy’

PhillipCapital's Chew has raised his FY2024 earnings on Sembcorp by 10% y-o-y to $912 million after the group's 1HFY2024 results.

Broker's Calls

Analysts react to DBS’s appointment of its next group CEO, 2QFY2024 results

The analysts' target prices range from $31.90 to $41.40.

Broker's Calls

Venture, FCT, Sats, Sembcorp and ComfortDelGro are stocks to seek ‘shelter’ in from a ‘weak’ August: DBS

An interest rate cut by the US Fed in September is a ‘near certainty’, says PhillipCapital, who is ‘overweight’ on REITs.

Broker's Calls

Maybank and PhillipCapital reduce target prices on SIA following 1QFY2025

Maybank and PhillipCapital have both kept their respective "hold" and "reduce" calls on SIA at reduced target prices.
×